SCHEMBL447590

SCHEMBL447590

C[C@@H](O)CCC[C@@H](O)CC(=O)O

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 4/20 0.61
SLC22A6 Q4U2R8 1/20 0.52
MAPT P10636 1/20 0.45
GABRR1 P24046 2/20 0.44
LMNA P02545 1/20 0.44
FFAR4 Q5NUL3 1/20 0.39
FFAR1 O14842 1/20 0.39
MMP12 P39900 4/20 0.38
MMP13 P45452 4/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP14 P50281 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2296708 1.00 GPR84 (0.61) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL15518119 1.00 GPR84 (0.61) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL23528833 0.93 GPR84 (0.70) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL21552704 0.93 GPR84 (0.70) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL4759399 0.93 GPR84 (0.70) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL28922166 0.88 GPR84 (0.67) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL4749028 0.86 GPR84 (0.61) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL667381 0.86 GPR84 (0.61) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL16600523 0.86 SLC22A6 (0.57) GPR84SLC22A6MAPTGABRR1LMNA
SCHEMBL27623054 0.84 SLC22A6 (0.55) GPR84SLC22A6MAPTGABRR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12439944-B2 3-hydroxybutyrate compounds for use in reducing liver fat TDELTAS LIMITED (GB) 2025-10-14 US claimed
US-11566268-B2 Process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-01-31 US claimed
US-10821062-B2 Compound for use in protecting skin TDELTAS LIMITED (GB) 2020-11-03 US claimed
US-10660958-B2 Nutritional composition TDELTAS LIMITED (GB) 2020-05-26 US claimed
EP-2539312-B1 NUTRITIONAL COMPOSITION TDELTAS LTD (GB) 2019-01-16 EP claimed
EP-1648952-B1 NUTRITIONAL SUPPLEMENTS AND THERAPEUTIC COMPOSITIONS COMPRISING (R)-3-HYDROXYBUTYRATE DERIVATIVES THE US GOV AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-03-07 EP claimed
US-20130102663-A1 NUTRITIONAL COMPOSITION TDELTAS LIMITED (GB) 2013-04-25 US claimed
US-20120064611-A1 Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2012-03-15 US claimed
EP-2419519-A1 PROCESS FOR THE PREPARATION OF (3R)-HYDR0XYBUTYL (3R) -HYDROXYBUTYRATE BY ENZYMATIC ENANTIOSELECTIVE REDUCTION EMPLOYING LACTOBACILLUS BREVIS ALCOHOL DEHYDROGENASE Isis Innovation Limited (GB) 2012-02-22 EP claimed
WO-2026090617-A1 PHARMACEUTICAL COMPOSITIONS AND POSTBIOTIC SUPPLEMENT COMPOSITIONS OF MICROBIALLY PRODUCED L-1,2-PROPANEDIOL AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-04-30 WO disclosed
US-20260108442-A1 COMPOUND FOR USE IN PROTECTING SKIN TDELTAS LTD (GB) 2026-04-23 US disclosed
EP-4721735-A1 COMPOSITION FOR ENTERAL NUTRITION OF CANCER PATIENTS Kyon Biotech AG (CH) 2026-04-08 EP disclosed
EP-4714505-A2 COMPOUND FOR USE IN PROTECTING SKIN Tdeltas Limited (GB) 2026-03-25 EP disclosed
EP-3860584-B1 COMPOUNDS FOR USE IN PREVENTING OR TREATING ATHLETE OVERTRAINING TDELTAS LTD (GB) 2026-02-18 EP disclosed
WO-2019234402-A1 COMPOUNDS FOR USE IN CANCER CACHEXIA TDELTAS LIMITED (GB) 2019-12-12 WO disclosed
EP-2539312-B1 NUTRITIONAL COMPOSITION TDELTAS LTD (GB) 2019-01-16 EP disclosed
EP-1648952-B1 NUTRITIONAL SUPPLEMENTS AND THERAPEUTIC COMPOSITIONS COMPRISING (R)-3-HYDROXYBUTYRATE DERIVATIVES THE US GOV AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-03-07 EP disclosed
US-20160030314-A1 COMPOUND FOR USE IN PROTECTING SKIN GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2016-02-04 US disclosed
EP-2968091-A1 COMPOUND FOR USE IN PROTECTING SKIN Tdeltas Limited (GB) 2016-01-20 EP disclosed
WO-2014139599-A1 COMPOUND FOR USE IN PROTECTING SKIN TDELTAS LIMITED (GB) 2014-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064611-A1 Process For The Preparation of (3R)-Hydroxybutyl (3R) -Hydroxybutyrate By Enzymatic Enantioselective Reduction Employing Lactobacillus Brevis Alcohol Dehydrogenase ADH5, ADH1A, ADH1C GPR84 1421/4885SLC22A6 3403/4885MAPT 3649/4885
US-20260108442-A1 COMPOUND FOR USE IN PROTECTING SKIN CUTA, POT1, CETP GPR84 3418/4885SLC22A6 2338/4885MAPT 552/4885
US-11566268-B2 Process for producing (R)-3-hydroxybutyl (R)-3-hydroxybutyrate HCAR3, HSD17B12, HSD17B10 GPR84 355/4885SLC22A6 2454/4885MAPT 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.